Omalizumab for asthma.
Strunk
Robert C
RC
Department of Pediatrics, Washington University School of Medicine, St. Louis, USA.
Bloomberg
Gordon R
GR
D000293:Adolescent; D000485:Allergens / Q000276:immunology; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D008297:Male; D000069444:Omalizumab; D017410:Practice Guidelines as Topic
D000485:Allergens; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E